TeraRecon awarded 2 AI patents for medical imaging technology

TeraRecon announced Monday, March 2, that its AI solutions have been awarded two technology patents from the U.S. Patent and Trademark Office.

The first patent, “System and Method for Medical Image Interpretation,” covers the company’s image analysis engine, including the machine learning-powered capabilities that help the technology evolve based on user modifications.

The second, “Medical Image Identification and Interpretation,” covers similar ground, also emphasizing AI that uses prior imaging findings to reach its conclusions.

“Prioritizing physician control over AI findings is key to garnering trust and achieving wide-spread clinical adoption,” Jeff Sorenson, TeraRecon CEO, said in a prepared statement. “These platform patents cover a wide and important range of image interpretation use cases, validating TeraRecon as the standard-bearer for interactive AI-driven radiology interpretation technology.” 

Additional information on these patents, including full PDFs, is available on the company’s website.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.